Big Pharma Can't Beat SF Opioid Claims Before Trial

By Lauren Berg (April 8, 2022, 8:05 PM EDT) -- Teva Pharmaceuticals, Allergan, Anda Inc. and other drugmakers and distributors can't escape San Francisco's claims in an upcoming bellwether bench trial, the California federal judge overseeing the multidistrict opioid litigation has ruled, but Endo International can beat allegations attributed to its subsidiaries.

U.S. District Judge Charles R. Breyer denied summary judgment to divisions of drug manufacturers Allergan and Teva, as well as distributor Anda over public nuisance and Unfair Competition Law claims, saying there are factual disputes over San Francisco's theories that the defendants made false statements about the safety and risks of opioids, and that they failed to use systems...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!